drugset / Trial / NCT03811548
Janagliflozin Treat T2DM Monotherapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the effect of Janagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 24 weeks of treatment, and to assess the efficacy after 52 weeks of treatment, overall safety and Population pharmacokinetics.
Timeline
- Start
- 2019-05-23
- Primary completion
- 2020-06-24
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Janagliflozin | Unknown | 25 mg | Oral |
| Subject | Janagliflozin | Unknown | 50 mg | Oral |